GT Biopharma Faces Delisting Concerns
Ticker: GTBP · Form: 8-K · Filed: Nov 26, 2025 · CIK: 109657
| Field | Detail |
|---|---|
| Company | Gt Biopharma, INC. (GTBP) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $1, $1 m, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
GT Biopharma might get delisted, filing shows.
AI Summary
GT Biopharma, Inc. filed an 8-K on November 26, 2025, reporting a notice of delisting or failure to meet continued listing requirements. The filing also includes financial statements and exhibits, with the earliest event reported being November 20, 2025. The company, formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates potential issues with GT Biopharma's continued listing on an exchange, which could significantly impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ongoing operations and stock market presence.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- OXIS INTERNATIONAL INC (company) — Former Company Name
- DDI PHARMACEUTICALS INC (company) — Former Company Name
- DIAGNOSTIC DATA INC /DE/ (company) — Former Company Name
- November 20, 2025 (date) — Earliest event reported
- November 26, 2025 (date) — Filing Date
FAQ
What is the primary reason for GT Biopharma's 8-K filing?
The primary reason is a notice of delisting or failure to satisfy a continued listing rule or standard.
When was the earliest event reported in this filing?
The earliest event reported was on November 20, 2025.
What are some of GT Biopharma's former company names?
GT Biopharma was formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/.
In which state is GT Biopharma, Inc. incorporated?
GT Biopharma, Inc. is incorporated in Delaware.
What is the SIC code for GT Biopharma, Inc.?
The Standard Industrial Classification (SIC) code for GT Biopharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 890 words · 4 min read · ~3 pages · Grade level 14.3 · Accepted 2025-11-26 16:30:40
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value GTBP The Nasdaq Stock Mar
- $1 — e (the "Common Stock") had closed below $1 per share for 30 consecutive business d
- $1 m — Company was not in compliance with the $1 minimum bid price requirement for continu
- $1.00 — the Company's Common Stock is at least $1.00 per share for a minimum of ten consecut
Filing Documents
- form8-k.htm (8-K) — 40KB
- 0001493152-25-025162.txt ( ) — 203KB
- gtbp-20251120.xsd (EX-101.SCH) — 3KB
- gtbp-20251120_lab.xml (EX-101.LAB) — 33KB
- gtbp-20251120_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT BIOPHARMA, INC. Date: November 26, 2025 By: /s/ Alan Urban Alan Urban Chief Financial Officer